"OPAL1 je transmembr\u00E1nov\u00FD adaptorov\u00FD protein exprimovan\u00FD zejm\u00E9na megakaryocyty a krevn\u00EDmi desti\u010Dkami. Krom\u011B toho jej jeho exprese zv\u00FD\u0161en\u00E1 u TEL/AML pozitivn\u00EDch leukemi\u00ED. P\u0159ipravili jsme dvojici monoklon\u00E1ln\u00EDch protil\u00E1tek proti tomuto antigenu. Ob\u011B jsou dob\u0159e pou\u017Eiteln\u00E9 pro pr\u016Ftokovou cytometrii i imunoblotting. OPAL1-01 bude nyn\u00ED testov\u00E1na na pacientsk\u00FDch vzorc\u00EDch. Ob\u011B protil\u00E1tky budou t\u00E9\u017E firmou Apronex nab\u00EDzeny prost\u0159ednictv\u00EDm partnersk\u00FDch distribu\u010Dn\u00EDch firem. Kvalitn\u00ED komer\u010Dn\u011B dostupn\u00E9 protil\u00E1tky proti proteinu OPAL1 nebyly dosud k dispozici. P\u0159edstavuj\u00ED tedy nov\u00E9 unik\u00E1tn\u00ED reagencie okam\u017Eit\u011B pou\u017Eiteln\u00E9 v z\u00E1kladn\u00EDm i aplikovan\u00E9m v\u00FDzkumu. P\u0159ipraven\u00E9 protil\u00E1tky slou\u017E\u00ED k detekci proteinu OPAL1 pomoc\u00ED imunoblotingu a pr\u016Ftokov\u00E9 cytometrie. Jsou tak z\u00E1kladn\u00EDm n\u00E1strojem studia exprese a funkce proteinu OPAL1 v lidsk\u00FDch bu\u0148k\u00E1ch. Po nutn\u00E9m testov\u00E1n\u00ED na pacientsk\u00FDch vzorc\u00EDch se mohou st\u00E1t i n\u00E1strojem i pro p\u0159\u00EDpadnou rutinn\u00ED diferenci\u00E1ln\u00ED diagnostiku leukemi\u00ED." . "P(2B06064), Z(AV0Z50520514)" . . . . "P\u0159\u00EDprava monoklon\u00E1ln\u00EDch protil\u00E1tek proti proteinu OPAL1" . "RIV/68378050:_____/10:00355230" . "Preparation of monoclonal antibodies to protein OPAL1"@en . . . "Preparation of monoclonal antibodies to protein OPAL1"@en . . "RIV/68378050:_____/10:00355230!RIV11-MSM-68378050" . . . "My\u0161\u00ED hybridomov\u00E9 bun\u011B\u010Dn\u00E9 linie produkuj\u00EDc\u00ED monoklon\u00E1ln\u00ED protil\u00E1tky rozpozn\u00E1vaj\u00EDc\u00ED protein OPAL1, v\u00FDsledek ov\u011B\u0159en pro zaveden\u00ED do v\u00FDroby" . . . "1"^^ . . "OPAL1; leukemia; monoclonal antibody; hybridoma"@en . "v\u00FDsledek p\u0159ipraven ke komer\u010Dn\u00EDmu vyu\u017Eit\u00ED na z\u00E1klad\u011B smlouvy o p\u0159ed\u00E1n\u00ED v\u00FDsledku realiz\u00E1torovi" . . "1"^^ . "[8958C79714DB]" . . . . "P\u0159\u00EDprava monoklon\u00E1ln\u00EDch protil\u00E1tek proti proteinu OPAL1"@cs . . . "Ho\u0159ej\u0161\u00ED, V\u00E1clav" . "281842" . . . . . "P\u0159\u00EDprava monoklon\u00E1ln\u00EDch protil\u00E1tek proti proteinu OPAL1"@cs . "realiz\u00E1tor Apronex s.r.o., I\u010C 27093123" . "OPAL1 je transmembr\u00E1nov\u00FD adaptorov\u00FD protein exprimovan\u00FD zejm\u00E9na megakaryocyty a krevn\u00EDmi desti\u010Dkami. Krom\u011B toho jej jeho exprese zv\u00FD\u0161en\u00E1 u TEL/AML pozitivn\u00EDch leukemi\u00ED. P\u0159ipravili jsme dvojici monoklon\u00E1ln\u00EDch protil\u00E1tek proti tomuto antigenu. Ob\u011B jsou dob\u0159e pou\u017Eiteln\u00E9 pro pr\u016Ftokovou cytometrii i imunoblotting. OPAL1-01 bude nyn\u00ED testov\u00E1na na pacientsk\u00FDch vzorc\u00EDch. Ob\u011B protil\u00E1tky budou t\u00E9\u017E firmou Apronex nab\u00EDzeny prost\u0159ednictv\u00EDm partnersk\u00FDch distribu\u010Dn\u00EDch firem. Kvalitn\u00ED komer\u010Dn\u011B dostupn\u00E9 protil\u00E1tky proti proteinu OPAL1 nebyly dosud k dispozici. P\u0159edstavuj\u00ED tedy nov\u00E9 unik\u00E1tn\u00ED reagencie okam\u017Eit\u011B pou\u017Eiteln\u00E9 v z\u00E1kladn\u00EDm i aplikovan\u00E9m v\u00FDzkumu. P\u0159ipraven\u00E9 protil\u00E1tky slou\u017E\u00ED k detekci proteinu OPAL1 pomoc\u00ED imunoblotingu a pr\u016Ftokov\u00E9 cytometrie. Jsou tak z\u00E1kladn\u00EDm n\u00E1strojem studia exprese a funkce proteinu OPAL1 v lidsk\u00FDch bu\u0148k\u00E1ch. Po nutn\u00E9m testov\u00E1n\u00ED na pacientsk\u00FDch vzorc\u00EDch se mohou st\u00E1t i n\u00E1strojem i pro p\u0159\u00EDpadnou rutinn\u00ED diferenci\u00E1ln\u00ED diagnostiku leukemi\u00ED."@cs . . "OPAL1-01" . "P\u0159\u00EDprava monoklon\u00E1ln\u00EDch protil\u00E1tek proti proteinu OPAL1" . "OPAL1 is a transmembrane adaptor protein expresed especially by megakaryocytes and platelets. Its expression is increased in TEL/AML positive leukaemia. No good antibodies to OPAL1 are available. We prepared two hybridoma cell lines producing mAbs to this protein. Good mAbs to protein OPAL1 have not yet been commercially available. Our mAbs therefore represent unique reagents immediately usable in basic and applied research. The mAbs are useful for detection of the protein OPAL1 by means of immunoblotting and cytofluorometry and represent basic tools for research on expression and function of the protein in human cells and may become diagnostic tools for routine differential diagnostics of leukaemia."@en .